ArticleAdvances in therapy2026
Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme™.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis real-world exploratory study in the United States (US) aimed to describe the socio-demographics, clinical characteristics, health-related quality of life (HRQoL), and work-related outcomes among people with obesity (PwO) undergoing a weight management program.
methodsSecondary data from the US cohort of Adelphi Real World Obesity III Disease Specific Programme™ (October 2023 and April 2024, and October 2024 and January 2025) were analyzed. This cross-sectional survey included physicians and their consulting PwO without T2D who had a physician-confirmed diagnosis of obesity [body mass index (BMI) ≥ 30 kg/m
resultsThe study included 1082 PwO (mean age: 47 years; female: 67.4%; tirzepatide: n = 199; OMM: n = 158; non-OMM: n = 725). The average time since OMM initiation was 7.4 months and 7.6 months for PwO in the tirzepatide and OMM groups, respectively. PwO in the tirzepatide group reported higher scores for most of the Short Form Health Survey version 2 (SF-36v2) domains than other groups; however, minimal differences were observed across all groups. A general trend towards greater work impairment among PwO in the non-OMM group than PwO in the tirzepatide and OMM groups was observed.
conclusionThis real-world exploratory study in the US suggests that PwO taking tirzepatide reported less impairment in some of the SF-36v2 domains than those not on tirzepatide. PwO on tirzepatide or alternative OMM treatment appeared to have numerically lower impairment in work-related outcomes than those not on treatment. These findings warrant evaluation for long-term impact of tirzepatide and OMMs on work-related and HRQoL outcomes among PwO.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.